Biolab Sanus Farmaceutica
- Company typePrivate
- Founded1997
- HeadquartersSão Paulo, Brazil
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
Biolab Sanus Farmaceutica firmographics
Firmographics- Name
- Biolab Sanus Farmaceutica
- Legal name
- Biolab Sanus Farmacêutica Ltda.
- Website
- https://biolabfarma.com.br
- Company type
- Private
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Ownership category
- akta.pro rank
Biolab Sanus Farmaceutica industry classification
Industry- Product category
- Pharmaceuticals (prescription and generic medications)
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Animal Food Manufacturing (3111), Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834), Food And Kindred Products (2000)
- akta.pro primary industry
- Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK)
Keywords
Where Biolab Sanus Farmaceutica is headquartered
LocationHeadquarters
- HQ city
- São Paulo
- HQ country
- Brazil
- HQ region
- Latin America
Offices7 records
Markets served
Biolab Sanus Farmaceutica business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- Pharmaceutical Products (Human Health): Revenue from branded pharmaceutical medications covering therapeutic areas including Cardiology, Dermatology, Gastroenterology, Mental Health (CNS), Women's Health, Urology, Pediatrics, Mobility/Orthopedics, and Hospital products. Products sold through pharmacies with prescription and OTC classifications.
- Generic Medications (Biolab Genéricos): Generic pharmaceutical products acquired from Actavis Brasil in 2018, positioning Biolab as 3rd in market share in the participative market (2022). Manufactured in same facilities as branded products with same quality standards.
- Veterinary Health Products (Avert): Veterinary pharmaceuticals, supplements, and dermocosmetics for pets (dogs and cats) with over 90 presentations. Division holds position among top 10 veterinary pharmaceutical companies for pet segment in Brazil.
- Pet Nutrition (Snacks and Treats): Pet snacks and treats acquired from Petitos in 2023, now integrated under Avert Saúde Animal. Products developed with natural, high-quality ingredients including meat for high palatability.
- Vitamins and Supplements: Dietary supplements including ID.Biolab line launched in 2019 for longevity and wellness, collagen supplements (Fascia line), and other nutritional products.
- International Licensing and Export: Revenue from international licensing-out partnerships including Vonau Flash exports to Latin America, Canada platform via Exzell Pharma acquisition, and partnerships with distributors in multiple countries.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Transaction based/ take rate | Pay-as-you-go | Programa Saúde em Evolução discount program with fixed percentage and amount discounts |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels9 records
Biolab Sanus Farmaceutica product offering
Product offeringCore offering
Biolab Sanus Farmaceutica is a Brazilian pharmaceutical company that develops, manufactures, and distributes branded prescription medications, generic drugs, vitamins and dietary supplements, dermatological and cosmetic products, and veterinary pharmaceuticals across 12 therapeutic areas. The company operates an enterprise field sales force of 1,800 representatives detailing physicians, distributes products through Brazilian pharmacies, hospitals, and clinics, and exports internationally via licensing-out partnerships and the Exzell Pharma Canada platform.
Product overview
Biolab Sanus Farmacêutica operates as a diversified pharmaceutical group (Biolab&Co since 2026) with over 500 products across multiple business units. The portfolio is structured in three main divisions: (1) Biolab Farmacêutica - branded prescription medications and dermocosmetics including cardiology (Vonau Flash®, Nebivolol), dermatology (Pantogar® hair/nail line, Contractubex®), and general health supplements (Fascia® collagen, Reaox®); (2) Biolab Genéricos - generic medications with 3rd place market share; and (3) Animal Health - Avert® Saúde Animal veterinary products and Pet Nutrition® pet snacks. The company also operates patient programs (Saúde em Evolução), digital platforms (Biolab Studio for healthcare professionals), and distributes internationally through Exzell Pharma (Canada). The portfolio spans 12 therapeutic categories including cardiology, dermatology, gastroenterology, mental health, pediatrics, urology, women's health, and mobility.
Differentiator
Problem solved
Functional benefit
Brands
- Biolab Genéricos: Generic pharmaceutical products division offering quality generic medications at accessible prices.
- Avert® Saúde Animal
- Pet Nutrition®
- Exzell Pharma
- Vonau Flash®
- Biolab Studio
- Biolab em Casa
Products and services
- Vonau Flash Antiemetic medication for treatment of nausea and vomiting in adults and children, featuring orodispersible tablet technology for accelerated relief. Developed in partnership with USP. Benefits over 6 million patients annually and has generated R$30 million in royalties for USP.
- Nebivolol (Nebilet) Third-generation beta-blocker for cardiovascular conditions featuring beta-3 receptor agonism that increases nitric oxide production and provides metabolic benefits. Available with 25% discount through Saude em Evolucao program.
Quantifiable outcome
- Vonau Flash benefits over 6 million patients annually and has generated R$30 million in royalties for the University of São Paulo (90% of total royalties received by the institution)
- +2 more outcomes
Companies that use Biolab Sanus Farmaceutica
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles3 records
Biolab Sanus Farmaceutica technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Biolab Sanus Farmaceutica partnerships and signals
Strategic signalPartnerships
21 partnerships are on record, tiered core, major and minor.
- Exzell PharmacoreCanadian pharmaceutical company acquired in 2022, establishing an international export platform from Canada with products for Gastroenterology, Dermatology, vitamins and supplements specialties.
- Merz PharmacoreJoint venture Merz-Biolab established in 2010, expanding international presence and launching the Procedure line including Xeomin botulinum toxin into the portfolio.
- University of São Paulo (USP)corePartnership with USP's Faculty of Pharmaceutical Sciences (FCF-USP) for development of Vonau Flash, one of the largest success cases of university-company partnership in Brazil with R$30 million in royalties to USP.
- Federal University of Rio Grande do Sul (UFRGS)corePartnership with UFRGS for development of Photoprot FPS 99 sunscreen using nanotechnology.
- MIT - Massachusetts Institute of TechnologymajorMember of MIT's Industrial Liaison Program (MIT-ILP) for innovation excellence.
- FIOCRUZ - Oswaldo Cruz FoundationmajorPartnership with Brazilian Oswaldo Cruz Foundation for health research.
- Instituto ButantanmajorPartnership with Instituto Butantan for research collaboration.
- UNICAMP - University of CampinasmajorPartnership with UNICAMP for research and development.
- UFMG - Federal University of Minas GeraismajorPartnership with UFMG for research collaboration.
- FAPESPmajorPartnership with São Paulo State Research Foundation FAPESP.
- UNIVAS - University of Vale do SapucaíminorPartnership with UNIVAS for research collaboration.
- HC-FMUSP - Hospital das ClínicasmajorPartnership with Hospital das Clínicas of USP for clinical research.
- Farma ColombiamajorLicensing-out distribution partner in Colombia.
- Grupo Farma Del EcuadormajorLicensing-out distribution partner in Ecuador.
- Farma VenezuelamajorLicensing-out distribution partner in Venezuela.
- Eurofarma (Mexico)majorLicensing-out distribution partner in Mexico.
- Biopharma Pharmaceutical CompanymajorLicensing-out distribution partner in UAE.
- Yahmaa Medical CompanymajorLicensing-out distribution partner in Saudi Arabia.
- Quimifar S.AminorLicensing-out distribution partner.
- QuifatexminorLicensing-out distribution partner.
- ANPEIminorMember of National Association of Research and Development of Innovative Companies (ANPEI) for strengthening commitment to national innovation.
Scale indicators12 records
Recent moves15 records
Expansion highlights6 records
Biolab Sanus Farmaceutica competitors and assessment
Company assessmentDirect peers
- Cristália: Brazilian pharmaceutical company with strong presence in hospital products, generics, and specialty pharma. Competes with Biolab in B2B hospital channels and the generics segment.
- Aché Laboratórios: Major Brazilian pharmaceutical company with strong presence in cardiology, dermatology, and CNS therapeutic areas where Biolab operates. Similar mid-to-large scale profile with focus on prescription and specialty pharma.
- Hypera Pharma: Brazilian pharma and consumer health leader (formerly Hypermarcas), operating across prescription pharma, OTC, and consumer health segments. Comparable diversification between branded pharma and consumer/OTC categories.
- Libbs Farmacêutica: Privately-held Brazilian pharmaceutical company with focus on women's health, dermatology, and specialty therapeutics. Comparable in scale, private ownership structure, and therapeutic mix.
- EMS Pharma: Largest Brazilian pharmaceutical company by sales, with strong generics and branded portfolios. Direct competitor to Biolab in the Brazilian pharmacy channel and in generics market share (where EMS typically leads).
- Eurofarma Laboratórios: Brazilian pharmaceutical company with a similarly diversified branded and generics portfolio across multiple therapeutic areas. Comparable in scale, commercial footprint, and international expansion focus via licensing and export partnerships.
Emerging players
- Mantecorp: Brazilian pharmaceutical brand now operating under Hypera, with focus on dermatology and women's health. Comparable branded pharma presence in similar therapeutic categories.
Broad incumbents
- Sanofi: Global pharmaceutical company with substantial Brazilian operations across cardiology, dermatology, vaccines, and consumer health. Competes with Biolab as a broad incumbent rather than as a Brazilian-focused specialist.
- Bayer: Global pharmaceutical company with established Brazilian presence. Overlaps with Biolab in cardiology and women's health categories, and is also a Biolab licensing-in partner.
Regional players
- Aurobindo Pharma: Indian pharmaceutical manufacturer with global generics footprint, particularly in emerging markets. Already a Biolab licensing-in partner; comparable in generics scale and emerging market expansion model.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Biolab Sanus Farmaceutica social profiles
Digital presenceBiolab Sanus Farmaceutica compliance and trust
Trust signalCompliance5 records
Biolab Sanus Farmaceutica financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biolab Sanus Farmaceutica leadership team
Management profileNumber of profiles
Profiles2 records
Biolab Sanus Farmaceutica subsidiaries and ownership
Company hierarchySubsidiaries8 records
Biolab Sanus Farmaceutica funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biolab Sanus Farmaceutica M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biolab Sanus Farmaceutica
What does Biolab Sanus Farmaceutica do?
Biolab Sanus Farmaceutica is a Brazilian pharmaceutical company that develops, manufactures, and distributes branded prescription medications, generic drugs, vitamins and dietary supplements, dermatological and cosmetic products, and veterinary pharmaceuticals across 12 therapeutic areas. The company operates an enterprise field sales force of 1,800 representatives detailing physicians, distributes products through Brazilian pharmacies, hospitals, and clinics, and exports internationally via licensing-out partnerships and the Exzell Pharma Canada platform.
Is Biolab Sanus Farmaceutica a public or private company?
Biolab Sanus Farmaceutica is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Biolab Sanus Farmaceutica founded?
Biolab Sanus Farmaceutica was founded in 1997. It employs 1,001 to 5,000 people.
Where is Biolab Sanus Farmaceutica based?
Biolab Sanus Farmaceutica is headquartered in São Paulo, Brazil, in the Latin America region.
How does Biolab Sanus Farmaceutica make money?
Six revenue lines are on record. Pharmaceutical Products (Human Health) is the primary driver. The others are generic Medications (Biolab Genéricos), veterinary Health Products (Avert), pet Nutrition (Snacks and Treats), vitamins and Supplements and international Licensing and Export.
Who are Biolab Sanus Farmaceutica's main competitors?
Direct peers on record are Cristália, Aché Laboratórios, Hypera Pharma, Libbs Farmacêutica, EMS Pharma and Eurofarma Laboratórios. Mantecorp is listed as an emerging player. Broad incumbents are Sanofi and Bayer. Aurobindo Pharma is listed as a regional player.
Does Biolab Sanus Farmaceutica have an API?
No public API is recorded for Biolab Sanus Farmaceutica.
What industry is Biolab Sanus Farmaceutica in?
Biolab Sanus Farmaceutica's product category is Pharmaceuticals (prescription and generic medications). Its primary akta.pro industry code is EUAAAIAK, Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives. Its NAICS code is 3254 and its SIC code is 2834.